Telix Pharmaceuticals Limited (OTCMKTS:TLPPF – Get Free Report)’s share price was up 12% during mid-day trading on Friday . The company traded as high as $12.48 and last traded at $12.22. Approximately 7,202 shares were traded during trading, an increase of 18% from the average daily volume of 6,118 shares. The stock had previously closed […]
TLX591 is an investigational anti-PSMA[1] radio-antibody-drug conjugate (rADC) therapy being developed for the treatment of mCRPC, differentiated by a short two-week dosing regimen.Reported
TLX591 is an investigational anti-PSMA[1] radio-antibody-drug conjugate rADC therapy being developed for the treatment of mCRPC differentiated by a short two-week dosing regimen Reported median radiographic progression-free survival rPFS is 88 months Builds on prior data from the ProstACT SELECT[2] trial demonstrating favourable safety profile and biodistribution[3] MELBOURNE Australia May 31 2024 PRNewswire Telix Pharmaceuticals Limited ASX TLX Telix the Company today announces additional positive datafrom the ProstACT SELECT trial SELECT of TLX591 177Lu rosopatamab tetraxetan a lutetium-labelled rADC therapy for the treatment of adult patients with PSMA-positive metastatic castrate-resistant prostate cancer mCRPC SELECT is a radiogenomics study intended to evaluate lesion concordance between 68Ga gallium-based PSMA-PET[4] imaging and TLX591 dosimetry for the purpose of validating PET imaging for patient selection for rADC therapy The Company has previously reported final safety data
Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer | Taiwan News taiwannews.com.tw - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from taiwannews.com.tw Daily Mail and Mail on Sunday newspapers.